Floatz logo

Rmc-9805

Thoracic Cancer

Tango Therapeutics, Inc.Phase 1/2Active
CC
45/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
81/ 100

Competitive context

6 Active assets in the Thoracic Cancer cohort.

Asset / SponsorPhaseRating
Atezolizumab
M.D. Anderson Cancer Center
Phase 2B
Docetaxel
Phase 3B
HYPERICUM
Phase 3B
Nivolumab
M.D. Anderson Cancer Center
Phase 1/2CCC
Catequentinib
JIANYANG WANG
Phase 2CCC

View all 23 →

Same molecule, other indications

Rmc-9805 is also rated in:

pancreatic ductal adenocarcinomaDormant
CCC
Indicative ·
50 / 100
View asset →
lung cancerDormant
CCC
Indicative ·
48 / 100
View asset →
non-small cell lung carcinomaDormant
CC
Indicative ·
46 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →